Embryology

Second Opinion Expert Announces OC FERTILITY® + OC BIOGENIX® To Join Its Panel To Provide Expert Second Opinions.

Retrieved on: 
Saturday, May 4, 2024
Patient, PCOS, PGT, Infertility, Freezing, Anesthesiology, SOE, ICSI, Fertility, Genetic testing, IVF, Embryology, MPH, DANA, OC, IUI, FACOG, Semen analysis

DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.

Key Points: 
  • DANA POINT, Calif., May 4, 2024 /PRNewswire-PRWeb/ -- SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility cases.
  • "We are honored to join the SOE panel to provide our expertise for challenging fertility cases and excited to leverage SOE's powerful second opinion platform as another way for us to help families," said Dr. Sharon Moayeri, founder and medical director of OC Fertility® + OC Biogenix®.
  • OC Fertility® + OC Biogenix® is a leading Southern California medical practice providing the best in fertility care and advanced laboratory services.
  • OC Fertility® + OC Biogenix®'s expert team features: Board-certified specialists, fellowship-trained in reproductive endocrinology, infertility, embryology, and anesthesiology, advanced public health education & advocacy and patient-centered, trauma-informed care.

H. Joseph Yost, Ph.D. Appointed Senior Vice Provost for Research

Retrieved on: 
Tuesday, April 23, 2024
American Heart, Society, University, Catholic University of America, Neuroanatomy, Creighton University, Genetics, The, Kabuki syndrome, Mouse, Catholic Church, Cell biology, Postdoctoral researcher, Mentorship, AAAS, Teaching, Neuroscience, Xenopus, Pediatrics, Developmental Biology (journal), Advancement, Research, R2, CHD, Zebrafish, Knowledge, Embryology, Public policy, Ventricular septal defect, Catholic higher education, IPSC, Faculty, National Science Board, Biology, Student, Biotechnology, Nursing

Washington, D. C., April 23, 2024 (GLOBE NEWSWIRE) -- A world-renowned scientist and researcher, H. Joseph Yost, Ph.D. has been appointed to the newly created position of senior vice provost for research at The Catholic University of America, where he will lead efforts to expand the University’s research capabilities and build upon the rich research tradition of the 137-year-old institution.

Key Points: 
  • Washington, D. C., April 23, 2024 (GLOBE NEWSWIRE) -- A world-renowned scientist and researcher, H. Joseph Yost, Ph.D. has been appointed to the newly created position of senior vice provost for research at The Catholic University of America, where he will lead efforts to expand the University’s research capabilities and build upon the rich research tradition of the 137-year-old institution.
  • Yost is coming to Catholic University from the University of Utah School of Medicine bringing more than three decades of teaching and research experience.
  • He is currently the Richard L. Stimson presidential endowed chair, vice chairman for basic science research in the department of pediatrics, and professor of neurobiology and anatomy.
  • “I am honored and deeply grateful for the opportunity to help build The Catholic University of America to a top tier research university.

Somite Raises $5.3M As Five Leading Scientists Join Forces To Incorporate AI In Stem Cell Therapy

Retrieved on: 
Tuesday, April 16, 2024
Embryology, Diabetes, Cell, AI, OpenAI, Muscular dystrophy, Trust, Computational biology, Research, Artificial intelligence, B cell, Entrepreneurship, Differentiable function, Dermis, Developmental biology, Venture, Biology, Cartilage, Behavior, MIT

BOSTON and AUSTIN, Texas, April 16, 2024 /PRNewswire/ -- Somite, a venture-backed company aiming to become the OpenAI of stem cell biology, announces that it has raised $5.3M in pre-seed funding. The round was led by Israel's preeminent Venture fund TechAviv, and joined by renowned Austin-based VCs Next Coast Ventures, Trust Ventures and Texas Venture Partners as well as NY-based Lerer Hippeau and others. The funds will be used to continue development of Somite's proprietary AlphaStem AI platform, building Somite labs and bringing the first therapeutic asset to phase 1 clinical trials. 

Key Points: 
  • The funds will be used to continue development of Somite's proprietary AlphaStem AI platform, building Somite labs and bringing the first therapeutic asset to phase 1 clinical trials.
  • Founded in October 2023, Somite is building AI foundation models to produce human tissue at scale for cell therapies.
  • "The future of medicine lies at the intersection of AI and biology," says Micha Breakstone, CEO and Co-Founder of Somite.
  • They are committed to advancing their groundbreaking stem cell therapy technology and have the power to transform the lives of millions of people by leveraging AI to produce human tissue for cell therapies."

3Daughters Announces Three New Appointments to Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Quotient, Thakeham, Alnylam Pharmaceuticals, CDMO, Birth, Labs, GSK plc, Pharmacy, University, Novartis, Dana–Farber Cancer Institute, IUD, University College London, Embryology, IND, MBA, Woman, Doctor of Philosophy, Intrauterine device, Therapy, Drug development, Allergan, Amersham plc, Takeda Oncology, Chief Justice of Hungary, Pharmacia, Birth control

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.

Key Points: 
  • Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.
  • An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial.
  • Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors.
  • With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare.

Leading Reproductive Expert Dr. Eva Schenkman Takes Helm as Director of Embryology Services at Gattaca Genomics

Retrieved on: 
Tuesday, February 27, 2024
Embryology, Education, IVF, ELD, ABB, Genomics, Entrepreneurship, Andrology, ALD, Genetic testing

Fort Lauderdale, Florida, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics proudly appoints renowned scientist, Dr. Eva Schenkman, as the Director of Embryology Services.

Key Points: 
  • Fort Lauderdale, Florida, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics proudly appoints renowned scientist, Dr. Eva Schenkman, as the Director of Embryology Services.
  • Dr. Schenkman's appointment as Director of Embryology Services signifies Gattaca Genomics' commitment to attracting top-tier talent in the field.
  • In her capacity as Director of Embryology Services, Dr. Schenkman will leverage her extensive experience in IVF laboratory management, andrology, and embryology to lead Gattaca Genomics in pioneering advancements in reproductive health.
  • Michael Carbonara, CEO of Gattaca Genomics says, "Dr. Eva Schenkman's appointment is a testament to Gattaca Genomics' commitment to excellence.

Pozitivf Secures $20 Million in Funding Led by MonCap to Democratize Fertility Treatment for All

Retrieved on: 
Thursday, February 22, 2024
SAN, Embryology, Inception, Investment, Physician, Fertility, IVF, Growth, Public health, Paco, University, Master, Safety, RMA, Child

SAN ANTONIO, Feb. 22, 2024 /PRNewswire/ -- Pozitivf, a rapidly expanding fertility clinic network making industry-leading fertility treatment more accessible to all, announced today that it raised $20 million in growth funding. The capital raise, one of the most significant awarded in the space, was led by MonCap. MonCap's investment was made out of its dedicated fertility fund which represents one of the market's largest and most strategic pools of capital specifically committed to expanding access to fertility-related care.

Key Points: 
  • The capital raise, one of the most significant awarded in the space, was led by MonCap.
  • Currently, a single IVF cycle can range from $15,000 to $30,000, rendering the procedure inaccessible for the vast majority of the population.
  • Leveraging decades of experience, Pozitivf employs lean management principles with an extreme focus on treatment details and process workflows to eliminate variability and overhead.
  • "We will make fertility care accessible to the vast majority of families across the globe," said Jonathan Sockol, Managing Partner of MonCap.

eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan

Retrieved on: 
Tuesday, February 13, 2024
Health Technology, Other Health, Technology, Stem Cells, Pharmaceutical, Surgery, Medical Devices, Genetics, Clinical Trials, Biotechnology, Science, Software, Veterinary, Other Science, Research, Health, Meiji University, Embryology, Cell, Doctor of Philosophy, Coagulation, Inflammation, Quality of life, Pelvic floor dysfunction, Transgene, Transplant, Genome, Patient, Gene, Kidney, Mortality, Tissue, Vaccine

eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, and PorMedTec, a global leader in porcine embryology, have successfully produced genetically engineered porcine donors in Japan for use in transplantation.
  • As part of a collaboration between the two companies, genetically engineered porcine cells developed by eGenesis were provided to PorMedTec for production using the somatic cell nuclear transfer, or cloning, process.
  • eGenesis and PorMedTec plan to jointly advance the development of genetically engineered organs in Japan to address the massive unmet need in the country, with an initial focus on kidney transplant.
  • “Cloning technology will enable the use of an alternative organ supply using genetically engineered porcine donors.

Illume Fertility Partners with TMRW Life Sciences to Provide Cutting Edge Technology for the Safe Management and Storage of Frozen Eggs and Embryos for Patients

Retrieved on: 
Tuesday, January 23, 2024
Patient, Fertility, Partner, IVF, Failure, Embryology, Risk, TMRW, Safety, Laboratory, FDA, Parent

NORWALK, Conn., Jan. 23, 2024 /PRNewswire-PRWeb/ -- Illume Fertility, a leading modern fertility practice whose exceptional quality of care helps hopeful parents grow their families, and TMRW Life Sciences, a fertility technology company, have partnered to provide Illume's patients with the world's first and only FDA-approved, automated platform for accurate management and storage of frozen eggs and embryos.

Key Points: 
  • "Tracking our patients' precious eggs and embryos is now completely digitized and seamless."
  • Illume Fertility is the only fertility center in Connecticut that has a TMRW cryo robot, and was one of the first fertility clinics in the United States to incorporate TMRW Life Sciences' automated platform into their lab.
  • The storage of eggs and embryos has always been a manual process in IVF laboratories, but with TMRW's automated platform, potential points of failure have been reduced by 93%.
  • Illume Fertility's clinicians have now modernized their specimen management and storage practices, utilizing TMRW's digital tools onsite in addition to transferring patient specimens offsite to and from TMRW Cryobanks.

CCRM FERTILITY ANNOUNCES CHELSEY LEISINGER AS NEW VP OF NETWORK LAB COMPLIANCE

Retrieved on: 
Monday, January 22, 2024
Patient, Fertility, Research, Iowa State University, IVF, Science, Embryology, University School, Bachelor of Science, Laboratory, Certification, Doctor of Philosophy, Veterinary medicine, University college, Medical device

LONE TREE, Colo., Jan. 22, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today the appointment of Chelsey Leisinger, MS, PhD, HCLD/CC as VP of Network Lab Compliance.

Key Points: 
  • Dr. Leisinger joins CCRM's leading team of fertility specialists, focusing on laboratory compliance
    LONE TREE, Colo., Jan. 22, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today the appointment of Chelsey Leisinger, MS, PhD, HCLD/CC as VP of Network Lab Compliance.
  • As the newly appointed Vice President of Network Lab Compliance for CCRM, Dr. Leisinger, a renowned fertility specialist, will play a pivotal role in supervising select laboratory locations.
  • Her primary focus will be on ensuring laboratory compliance and risk mitigation, thereby elevating the fertility experience for both CCRM laboratory technologists and patients.
  • "I am thrilled to join the CCRM Fertility expert team to help further the mission of providing top-notch fertility care," said Dr. Leisinger.

Markham Fertility Centre Adds Industry Veteran to its Leadership Team

Retrieved on: 
Wednesday, November 15, 2023
Health, Fertility, Pathology, Patient, Embryology, Appropriate Infrastructure Development Group, Service, Medical laboratory, Mentorship, Philosophy, University, Knowledge, Mount Sinai Hospital, Human, MSF, Medical device, MFC

Crystal Chan, co-owners of Markham Fertility Centre (MFC) proudly announce that Mark Evans, one of the top healthcare directors in the country in assisted reproduction, will be joining MFC as its Managing Director effective December 1, 2023.

Key Points: 
  • Crystal Chan, co-owners of Markham Fertility Centre (MFC) proudly announce that Mark Evans, one of the top healthcare directors in the country in assisted reproduction, will be joining MFC as its Managing Director effective December 1, 2023.
  • He led the Ottawa Fertility Centre between 2005 and 2015, where he collaborated with some of the most recognized fertility specialists and lab scientists in the country.
  • Dr Meivys Garcia, Medical Director and co-owner of MFC states: “We are thrilled to welcome Mark Evans to our leadership team.
  • Markham Fertility Centre is more than a fertility clinic, it is a vehicle to positively impact the lives of others, whether they be patients, employees, or the broader community.